Pilot study on the relationship between albumin administration and changes in the transcriptomic profile. An investigation in patients from the PREDICT Study receiving albumin as treatment for several complications during clinical course.
Richard Moreau (EF Clif. Paris, France)
Joan Clària (Hospital Clínic Barcelona-IDIBAPS; EF Clif. Barcelona, Spain)
Emmanuel Weiss (INSERM. Paris, France)
Promoter: EF Clif
Start date: 01/01/2020
End date: 30/04/2021
The objective of the study is to use whole-blood RNA sequencing (RNA-seq) data obtained in patients of the PREDICT study, to investigate the effects of intravenous albumin on circulating immune cells from patients with severe forms of acutely decompensated cirrhosis.
Thirty-seven patients without shock have been investigated using whole-blood RNA sequencing (RNA-seq), that was performed twice in 18 patients (before and after albumin administration), and once in 19 patients not receiving albumin. Whole-blood RNA-seq data were obtained once in 10 healthy subjects. We uncovered that those patients who had not received albumin had a generalized decrease in RNA signatures of lymphoid cells and that albumin electively abrogated the decline in RNA signatures of B cells. These findings prompted us to perform additional studies in 31 new patients with acutely decompensated assigned to either whole-blood RNA-seq (to explore the effects of albumin in patients with septic shock), bulk RNA-seq in peripheral blood mononuclear cells (PBMCs), blood flow cytometry, or single-cell RNA-seq (scRNA-seq) in PBMCs). Results have been used to write a first report that has been submitted for publication.